Factory Ponatinib Pharmaceutical Grade Ponatinib

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Ponatinib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Ponatinib
• CAS Number: 943319-70-8
• Molecular Formula: C29h27f3n6o
• Molecular Weight: 532.56 G/Mol
• Appearance: White to off-White Powder
• Identification: Retention Time Matches Reference Standard
• Water Content: ≤ 0.5%
• Residual Solvents: Meets Ich Q3c Limits
• Heavy Metals: ≤ 20 Ppm
• Melting Point: 198°c - 202°c
• Flow Rate: 1.0 Ml/Min
• Detection: UV @ 260 Nm
• Injection Volume: 10 µl
• Column: C18 (e.g., Zorbax Sb-C18, 4.6 × 150 mm, 5
• System Suitability: Rsd ≤ 2.0%
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS
• Origin: Xian
• Production Capacity: 300 Kg/Month

Product Description

Factory Ponatinib Pharmaceutical Grade Ponatinib 

Product Description

Product Details

Product Name	Ponatinib
Appearance	White to off-white powder
MW	532.56 g/mol
MF	C29H27F3N6O
CAS	943319-70-8

Ponatinib is an oral third-generation tyrosine kinase inhibitor (TKI) developed by Ariad Pharmaceuticals (now part of Takeda Pharmaceuticals), primarily used for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL). Its unique chemical structure can overcome common BCR-ABL1 mutation resistance, especially T315I mutation. This drug was approved by the US FDA in 2012 and is suitable for patients who are resistant or intolerant to other TKI drugs. It is an important treatment option for refractory leukemia.

Application&Function

Ponatinib effectively inhibits the activity of BCR-ABL1 fusion protein and its mutants (including T315I), blocks abnormal signal transduction, and thus inhibits the proliferation and survival of leukemia cells. In addition, it can also target and inhibit various kinases such as FGFR, PDGFR, VEGFR, etc., and has a broad-spectrum anti-tumor effect. Clinical studies have shown that Ponatinib can significantly improve the remission rate and prolong survival in drug-resistant CML and Ph+ALL patients, but caution should be exercised about its potential cardiovascular toxicity risks.

Specification

ABOUT US